KRT17 confers increased resistance to cisplatin in cervical cancer [33] and bladder cancer [34], and elevated expression of this gene was described to correlate with poor survival in oropharyngeal squamous cell carcinoma [35]. Here, KRT17 is linked to urinary bladder carcinoma.